Company Overview and News

 
Safran reports 10% organic revenue growth in first half

2018-09-07 janes
French defence and aerospace manufacturer Safran generated revenues of EUR9.5 billion (USD11.1 billion) in the first half of 2018, according to financial results released on 6 September. The result amounts to a 10.1% rise in organic revenue compared to the same period in 2017. The company's income also rose to EUR1.4 billion, an improvement of 32.6%, or of 20.3% excluding the impact of recent acquisition Zodiac Aerospace.
ZODFF ZC ZODFY

15
UPDATE 1-Safran raises 2018 targets after beating H1 forecasts

2018-09-06 reuters
PARIS, Sept 6 (Reuters) - France’s Safran hiked full-year forecasts after posting better-than-expected sales and profit in the first half on strong demand for spares and services, and said the switch in its factories to a new model of jet engine was going as planned.
DUAVF AM GEC GE GNE ZODFF ZC ZODFY

4
In-flight Entertainment & Connectivity (IFEC) Market worth $7.65 Bn by 2023

2018-08-27 asdnews
According to the latest market research report, now available on ASDReports, "In-flight Entertainment & Connectivity (IFEC) Market by End User (OEM, Aftermarket), Aircraft Type (NBA, WBA, VLA, Business Jets), Product (IFE Hardware, IFE Connectivity, IFE Content), and Region - Global Forecast to 2023", The In-flight Entertainment & Connectivity (IFEC) market is estimated to be USD 5.03 billion in 2018 and is projected to reach USD 7.
HON HON ZODFF GOGO COL ZC ZODFY

 
Bombardier Confident in New CRJ Cabin Supply Chain

2018-07-18 aviationweek
Bombardier is confident that interiors supply-chain challenges that plagued its C Series program will not be an issue on its new CRJ Atmosphère cabin, even though the supplier – Zodiac Aerospace – is the same.
ZODFF ZC ZODFY

2
Pertunjukan Udara Farnborough 2018 Menandakan Debut Kabin ATMOSPHÈRE Baharu Bombardier

2018-07-17 globenewswire
MONTRÉAL, July 17, 2018 (GLOBE NEWSWIRE) -- Pesawat Komersial Bombardier mendedahkan ruang dalam pesawat CRJ Series pertama dengan rekaan kabin ATMOSPHÈRE pada hari pembukaan Pertunjukan Udara Antarabangsa Farnborough di United Kingdom.
ZODFF DAL ZC ZODFY

 
봄바디어, 2018 판버러 국제 에어쇼에서 신규 Atmosphère 객실 선보여

2018-07-17 globenewswire
캐나다 몬트리올, July 17, 2018 (GLOBE NEWSWIRE) -- 봄바디어 커머셜 에어크래프트(Bombardier Commercial Aircraft)가 영국에서 개최된 판버러 국제 에어쇼 개막일에 신규 ATMOSPHÈRE 객실 디자인을 적용한 첫 CRJ 시리즈 항공기 외관을 공개했다.
ZODFF ZC ZODFY

2
La nueva cabina ATMOSPHÈRE de Bombardier debuta en el Salón Aeronáutico de Farnborough 2018

2018-07-17 globenewswire
MONTREAL, July 17, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft presentó el interior del primer avión de la CRJ Series con el nuevo diseño de la cabina ATMOSPHÈRE en la inauguración del Salón Aeronáutico de Farnborough en el Reino Unido.
ZODFF DAL ZC ZODFY

2
Une première pour la nouvelle cabine ATMOSPHÈRE de Bombardier au salon de l’aéronautique de Farnborough 2018

2018-07-16 globenewswire
MONTRÉAL, 16 juill. 2018 (GLOBE NEWSWIRE) -- Bombardier Avions commerciaux a dévoilé l’intérieur du premier avion régional CRJ Series doté de la nouvelle cabine ATMOSPHÈRE, le jour même de l’ouverture du salon international de l’aéronautique de Farnborough, au Royaume-Uni.
BDRPF ZODFF DAL ZC ZODFY

2
2018 Farnborough Air Show Marks Debut of Bombardier New ATMOSPHÈRE Cabin

2018-07-16 globenewswire
MONTRÉAL, July 16, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft unveiled the interior of the first CRJ Series aircraft with the new ATMOSPHÈRE cabin design on the opening day of the Farnborough International Air Show in the United Kingdom.
ZODFF DAL ZC ZODFY

 
Bombardier Confident In New CRJ Cabin Supply Chain

2018-07-12 aviationweek
MONTREAL—Bombardier is confident that interiors supply-chain challenges that plagued its C Series program will not be an issue on its new CRJ Atmosphere cabin, even though the supplier—Zodiac Aerospace—is the same. “We don’t anticipate any particular issue on the platform, and the ramp-up is going extremely well,” Bombardier Commercial Aircraft (BCA) VP and head of Patrick Baudis said during a recent briefing here ahead of the Farnborough .
ZODFF ZC ZODFY

2
Aerospace on course for massive M&A boom

2018-07-12 telegraph.co.uk
The aerospace sector is at the beginning of a mergers and acquisitions bonanza as the industry’s leaders rethink their business models and digital technology drives change, according to a new research paper.
ZODFF UTX COL ZC ZODFY OA

11
It’s not your imagination, airline restrooms are getting smaller

2018-07-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
SAF BOE AAL JBLU ZODFF UAL COL BA DAL ZC ZODFY

11
It's Not Your Imagination, Airline Restrooms Are Getting Smaller - Bloomberg

2018-07-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SAF BOE AAL JBLU ZODFF UAL COL BA DAL ZC ZODFY

14
UPDATE 1-Aerospace group Safran sticks to LEAP engine targets, no 'bad surprises' at Zodiac

2018-05-30 reuters
PARIS (Reuters) - French aerospace firm Safran (SAF.PA) is sticking to production targets for the LEAP jet engine, but is still unwilling to back proposals for higher output from Airbus and Boeing until it is convinced its own suppliers can keep up, its chief executive said on Wednesday.
DUAVF AM GEC GE GNE ZODFF ZC ZODFY

14
Safran repeats LEAP engine targets, says no 'bad surprises' at Zodiac

2018-05-30 reuters
PARIS, May 30 (Reuters) - The head of France’s Safran on Wednesday reaffirmed production targets for the LEAP aircraft engine co-produced with General Electric and predicted the engine that it replaces, the CFM56, would also stay in production through 2020.
GEC GE GNE ZODFF ZC ZODFY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:ZC / ZODIAC AEROSPACE on message board site Silicon Investor.

EZchip Semiconductor EZchip Semiconductor EZchip Semiconductor ezch ezch ezch
ZContest ZContest ZContest AZCO Mining AZCO Mining AZCO Mining
EZCO - Ezcony Interamerica Inc EZCO - Ezcony Interamerica Inc EZCO - Ezcony Interamerica Inc AZCAR: Riding the Digital Broadcast Wave AZCAR: Riding the Digital Broadcast Wave AZCAR: Riding the Digital Broadcast Wave
AZCO MINING (AZC) AZCO MINING (AZC) AZCO MINING (AZC) YZC - Yanzhou Coal Mining - IPO priced at $15.75 YZC - Yanzhou Coal Mining - IPO priced at $15.75 YZC - Yanzhou Coal Mining - IPO priced at $15.75
AZC - AZCO MININGS (AMEX:AZC) AZC - AZCO MININGS (AMEX:AZC) AZC - AZCO MININGS (AMEX:AZC) MUZC - GUNSLINGER RECORDS MUZC - GUNSLINGER RECORDS MUZC - GUNSLINGER RECORDS